hOX40

• Flow cytometry (FACS) analysis data of lymph node T-cells collected from humanized OX40 mice

Fig 1. Expression of OX40 in the spleen lymphocytes of humanized OX40 mice is detected by FACS.

The spleen lymphocytes of heterozygous humanized OX40 mice were activated by anti-CD3 and anti-CD28 for 48 hours, and then collected for staining. Along with a group undergoing no stimulation, the expression of murine and human OX40 was detected by FACS. The results showed that the active expression of human OX40 can be detected in both activated CD4+ and CD8+ T lymphocytes collected from heterozygous humanized OX40 mice, and the expression trend of human OX40 and murine Ox40 was similar.

• In vivo validation in a MC38 tumor-bearing model of humanized OX40 mouse.

  
  

• Case study 1

Fig 2. OX40 antibody showed dose-dependent anti-tumor activity in human OX40  knock-in mice bearing MC38 tumors. The OX40 antibody  was obtained from Innoventbio.

• Case study 2

Fig 3 IBI101 showed dose-dependent anti-tumor activity and  enhanced tumor-specific CD8+ T cell response in human OX40  knock-in mice bearing MC38 tumors. a Tumor growth curve of mice  treated with different doses of IBI101 alone or in combination with  anti-mouse PD-1 antibody. Different doses of IBI101 and anti-mouse PD-1 antibody were administrated as indicated by the arrow heads  after MC38 cells implantation. b Animal body weights were measured during the time course of the experiment. c Mice were injected with h-IgG (10  mg/kg), IBI101 (10  mg/kg), anti-PD-1 (0.5  mg/kg)  alone or IBI101  (10 mg/kg)+anti-PD-1  (0.5 mg/kg) at day 10 and  14 post tumor cell implantation. At day 17, tumor and spleen were  collected and analyzed by flow cytometry for the absolute counts of  the indicated cell subsets in tumor and d proportions of indicated cell  subsets in CD45+ splenocytes. Flow cytometry results showing the  proportions of cytokine-secreting cancer-specific CD8+ and CD4+ T  cells from tumor (e) and spleen (f) (n≥5) (In collaboration with Innoventbio)